Stock VRCA VERRICA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Verrica Pharmaceuticals Inc.

Equities

VRCA

US92511W1080

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
6.65 USD -2.06% Intraday chart for Verrica Pharmaceuticals Inc. -3.62% -9.15%
Mar. 26 Verrica Pharmaceuticals' Ycanth Gets New Chemical Entity Status, Orange Book Listing MT
Mar. 26 Verrica Pharmaceuticals Announces that YCANTH? Receives New Chemical Entity Status and Orange Book Listing from the FDA CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
GL
Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA
AQ
Verrica Pharmaceuticals' Ycanth Gets New Chemical Entity Status, Orange Book Listing
MT
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
GL
Verrica Pharmaceuticals Announces that YCANTH? Receives New Chemical Entity Status and Orange Book Listing from the FDA
CI
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
BU
HC Wainwright Adjusts Verrica Pharmaceuticals Price Target to $13 From $12, Maintains Buy Rating
MT
Transcript : Verrica Pharmaceuticals Inc., Q4 2023 Earnings Call, Feb 29, 2024
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Earnings Flash (VRCA) VERRICA PHARMACEUTICALS Reports Q4 Revenue $2M, vs. Street Est of $950,000
MT
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
GL
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
GL
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
GL
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
AQ
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
BU
Verrica Pharmaceuticals Sues Dormer Labs for Promoting Unapproved Cantharidin Drugs in US
MT
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
GL
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
AQ
Verrica Pharmaceuticals Receives Permanent J-Code for YCANTH from Centers for Medicare and Medicaid Services
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VRCA Stock
  4. News Verrica Pharmaceuticals Inc.